If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Product Launch » Product Launch Excellence
Download FREE Excerpt
55 Info Graphics
6 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The next big step in the long fight against cancer took place in the fall of 2017 when Novartis and Gilead launched the first generation of chimeric antigen receptor T-cell (CAR-T) therapies. The therapies - both based around using a patient's own re-engineered T-cells to attack their cancer - won priority reviews and quick approvals based on significant early results. The therapies meant a one-time treatment could mean lasting remission, even for the sickest patients.
The potential of Novartis' Kymriah and Gilead's Yescarta fueled blockbuster projections from analysts and a flurry of industry interest in CAR-T development. But large price tags ($373,000 - $475,000), manufacturing challenges, and serious side effects have stymied wide-scale utilization of the therapies.
Why have these promising drugs under-performed, and what is the future of CAR-T?
Best Practices, LLC conducted an extensive research project to examine the genesis, launch and market struggles of these ground-breaking therapies. "CAR-T & Cell Therapy Products: Next generation of oncology products create chance for boom or bust" is a new 78-page case study that examines:
· CAR-T's pathway to the marketplace
· Kymriah's and Yescarta's market entry strategies…and slow launch curves
· The manufacturing and pricing challenges facing CAR-T therapies
· Why payers and pharma need to find reimbursement common ground
· What the future holds for next generation CAR-T therapies and pharma
Novartis and Gilead each took billon-dollar gambles with CAR-T, and now face heavy headwinds from payers that have hit the pause button to figure out how to afford $400,000 products. But the possibilities of CAR-T as a powerful weapon against other cancers has attracted an unprecedented wave of new T-cell therapy companies - as well as Top 10 pharma companies - that are investing heavily in next generation CAR-T products.
This study pulls together multiple sources of information across key issues affecting CAR-T development and launch to give new product development leaders critical insights into the potential and challenges facing CAR-T development and launch.
The report was based on extensive secondary research that involved dozens of industry, media, company and government reports and regulatory filings.
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.